Harvard College

The Brigham and Women's Hospital, Inc.

Massachusetts Institute of Technology

Children's Medical Center Corporation

The Cbr Institute for Biomedical Research, Inc.

Other

Immune Disease Institute, Inc.

Ulrich Von Andrian

Omid C Farokhzad

Pamela A Basto

Robert Samuel Langer

Matteo Iannacone

Elliott Ashley Moseman

Frank Alexis

Jinjun Shi

Elena Tonti

Liangfang Zhang

Tobias Junt

Robert S Langer

Aude Thiriot

Klavs F Jensen

Darrell J Irvine

Armon R Sharei

Siddharth Jhunjhunwala

Jean-Marc Gauguet

Irina Mazo

Shirley Mao

George Hartoularos

Sophia Liu

Megan Heimann

Aleksandar Filip Radovic-Moreno

Thomas S Kupper

Robert S Langer, Jr

Michael N Starnbach

Robert Langer

Gregory Lee Szeto

Xi Zhu

Stephen Byron Shohet

Xiaoding Xu

Nazila Kamaly

Silke Paust

Yanlan Liu

Georg Stary

Gregory Szeto

Irwin Sherman

Won Il Choi

Caroline Robert

Pamela Basto

Ashley Moseman

A method and device for preferentially delivering a compound such as an antigen to the cytosol of an immune cell. The method comprises passing a cell suspension comprising the target immune cell through a microfluidic device and contacting the suspension with the compound(s) or payload to be delivered.

Delivery of biomolecules to immune cells

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at least one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.

Vaccine nanotechnology

This invention relates to amphiphile-polymer particles comprising obtaining a first solution comprising a water-insoluble polymer, a payload and a first amphiphile in a water-miscible solvent; mixing the first solution with an aqueous second solution to form an aqueous composition comprising a particle comprising a water-insoluble polymeric core comprising the water-insoluble polymer; the payload; and the first amphiphile.

Amphiphile-polymer particles

Provided herein are new compositions including an inactivated pathogen and one or more adjuvant-loaded polymeric nanoparticles, wherein the adjuvant-loaded nanoparticles are bound to the inactivated pathogen. These compositions are useful for preventing and/or treating diseases caused by the specific pathogens, especially when administered to a subject's mucosal membranes.

Nanoparticle-based compositions

Disclosed herein are microvessel endothelial cell surface markers and methods, compositions, agents, and kits relating to those surface markers.

Microvessel endothelial cell surface markers and uses thereof

This disclosure relates to nanoparticles, compositions, methods of making, and methods of use thereof.

Nanoparticles and methods of use

Disclosed herein are genes which are differentially expressed in venule endothelial cells (V-ECs) compared to non-venule endothelial cells (NV-ECs) and methods and compositions relating to those genes. Also disclosed herein are methods of modulating the venuleness of an endothelial cell or microvessel, methods of modulating leukocyte trafficking, methods of modulating inflammation, methods of targeting agents to tissues based on their ability to bind to surface markers expressed in a microvessel (e.g., venules and non-venules), methods of identifying the venuleness of endothelial cells or microvessels, methods of identifying agents that modulate the venuleness of endothelial cells or microvessels, methods of identifying agents that target microvessels, methods for treating diseases associated with leukocyte trafficking, methods for treating inflammatory diseases, and compositions and kits for use in the methods.

Venule endothelial cell genes and uses thereof

The present invention demonstrates that bisphosphonates have an intrinsic adjuvant activity and directly stimulate B cell antibody secretion. Accordingly, the present invention provides vaccines comprising a bisphosphonate, methods for stimulating an immune response, enhancing the immunogenicicty of an immunogen, and methods of treating an infection, an autoimmune disease, an allergy, and/or a cancer using the same.

Vaccines comprising bisphosphonate and methods of use thereof

The instant invention is based, at least in part, on the discovery that CXCR6 plays a critical role in antigen-specific effector function of NK cells. Accordingly, the invention provides, among other things, methods for modulation of antigen-specific NK cell effector function, methods for identifying modulators of antigen-specific NK cell effector function.

Modulation of NK cell antigen specific effector activity by modulation of CXCR6 (CD186)

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.

Adjuvant incorporation in immunoanotherapeutics

Growing community of inventors

Chestnut Hill, MA, United States of America

Ulrich Von Andrian